CN115776894A - T型钙通道调节剂的使用方法 - Google Patents

T型钙通道调节剂的使用方法 Download PDF

Info

Publication number
CN115776894A
CN115776894A CN202180046763.8A CN202180046763A CN115776894A CN 115776894 A CN115776894 A CN 115776894A CN 202180046763 A CN202180046763 A CN 202180046763A CN 115776894 A CN115776894 A CN 115776894A
Authority
CN
China
Prior art keywords
dose
compound
subject
period
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046763.8A
Other languages
English (en)
Chinese (zh)
Inventor
K·雷迪
G·贝尔福特
B·拉维纳
M·怀特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Pharmaceuticals
Original Assignee
Praxis Precision Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Pharmaceuticals filed Critical Praxis Precision Pharmaceuticals
Publication of CN115776894A publication Critical patent/CN115776894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Transmitters (AREA)
CN202180046763.8A 2020-04-29 2021-04-28 T型钙通道调节剂的使用方法 Pending CN115776894A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US63/017,140 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US63/050,410 2020-07-10
US202063082946P 2020-09-24 2020-09-24
US63/082,946 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
CN115776894A true CN115776894A (zh) 2023-03-10

Family

ID=78373913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046763.8A Pending CN115776894A (zh) 2020-04-29 2021-04-28 T型钙通道调节剂的使用方法

Country Status (11)

Country Link
US (1) US20230165847A1 (https=)
EP (1) EP4142764A4 (https=)
JP (1) JP2023524039A (https=)
KR (1) KR20230018384A (https=)
CN (1) CN115776894A (https=)
AU (1) AU2021263804A1 (https=)
BR (1) BR112022021946A2 (https=)
CA (1) CA3177277A1 (https=)
IL (1) IL297642A (https=)
MX (1) MX2022013595A (https=)
WO (1) WO2021222342A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340670B (zh) 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
US20250170114A1 (en) * 2022-02-03 2025-05-29 Praxis Precision Medicines, Inc. Methods of treatment using t-type calcium channel modulators
AU2023244348A1 (en) * 2022-03-28 2024-10-10 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
EP4522271A4 (en) * 2022-05-09 2026-04-29 Praxis Prec Medicines Inc Methods of use of t-type calcium channel modulators
EP4673219A1 (en) * 2023-03-02 2026-01-07 Praxis Precision Medicines, Inc. Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
AU2024229946A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Crystalline salts of a t-type calcium channel modulator and methods of use thereof
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
US20180280357A1 (en) * 2015-10-22 2018-10-04 Cavion, Inc. Methods for treating angelman syndrome and related disorders
US20180312471A1 (en) * 2015-11-12 2018-11-01 Afasci, Inc. Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
CN110072521B (zh) * 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
AU2018364659A1 (en) * 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
IL300798B2 (en) * 2018-10-03 2025-09-01 Cavion Inc Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
CN114340670B (zh) * 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP4522271A4 (en) * 2022-05-09 2026-04-29 Praxis Prec Medicines Inc Methods of use of t-type calcium channel modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180280357A1 (en) * 2015-10-22 2018-10-04 Cavion, Inc. Methods for treating angelman syndrome and related disorders
US20180312471A1 (en) * 2015-11-12 2018-11-01 Afasci, Inc. Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIZABETH TRINGHAM 等: "T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures", 《SCI TRANSL MED.》, vol. 4, no. 121, 15 February 2012 (2012-02-15), pages 1 - 13, XP055373087, DOI: 10.1126/scitranslmed.3003120 *
PABLO MIGUEL CASILLAS-ESPINOSA等: "Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model", 《PLOS ONE》, vol. 10, no. 8, 14 August 2015 (2015-08-14), pages 1 - 12 *
吕楠;肖波;: "T型钙离子通道在癫痫发生中的作用研究进展", 中国神经精神疾病杂志, no. 07, 27 July 2013 (2013-07-27), pages 447 - 449 *

Also Published As

Publication number Publication date
CA3177277A1 (en) 2021-11-04
IL297642A (en) 2022-12-01
MX2022013595A (es) 2023-01-24
WO2021222342A1 (en) 2021-11-04
EP4142764A4 (en) 2024-05-29
BR112022021946A2 (pt) 2023-01-17
EP4142764A1 (en) 2023-03-08
KR20230018384A (ko) 2023-02-07
AU2021263804A1 (en) 2023-01-19
US20230165847A1 (en) 2023-06-01
JP2023524039A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
WO2023150703A2 (en) Methods of treatment using t-type calcium channel modulators
US20250375380A1 (en) High strength single unit dose formulations and methods of use thereof
CN121943902A (zh) T-型钙通道调节剂的制剂及其使用方法
CN121943903A (zh) T-型钙通道调节剂的制剂及其使用方法
CN121943904A (zh) T-型钙通道调节剂的制剂及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination